Japan Vaccines Market Research Report, 2028

The Japan Vaccines market is expected to reach a market size of more than USD 4 Billion by 2028.

Japanese culture places a significant emphasis on preventive healthcare. People are encouraged to maintain a healthy lifestyle through balanced nutrition, regular exercise, and stress management to prevent illness. Japan has a rapidly ageing population, and there is a strong cultural tradition of respecting and caring for elderly family members. Many families take on the responsibility of caring for their elderly parents or grandparents at home. Vaccine hesitancy has been a notable feature of Japan's vaccine culture. In the past, concerns about vaccine safety, particularly those related to adverse events, led to a decline in vaccination rates for certain diseases like measles, mumps, and rubella (MMR). This hesitancy was fueled by media reports and public anxiety. The incident in the late 1980s involving the MMR vaccine and cases of aseptic meningitis in Japan significantly eroded public trust in vaccines. Subsequently, Japan suspended the MMR vaccine from its routine vaccination schedule, leading to outbreaks of these diseases. The country has a rigorous vaccine approval process. While this process ensures high standards of vaccine safety and efficacy, it can also contribute to delays in introducing new vaccines to the market. In response to vaccine hesitancy and disease outbreaks, the Japanese government has launched public awareness campaigns to rebuild trust in vaccines. These campaigns aim to educate the public about the importance of vaccination and dispel misconceptions. In recent years, Japan has introduced stricter school vaccination requirements to improve vaccine coverage among school-age children. These requirements help protect the population from vaccine-preventable diseases. Japan's universal healthcare system ensures that vaccines are accessible and affordable for all citizens. This contributes to overall vaccine coverage and public health. According to the research report "Japan Vaccines Research Report, 2028," published by Actual Market Research, the Japan Vaccines market is expected to reach a market size of more than USD 4 Billion by 2028. The Japanese government has implemented various initiatives to improve vaccination rates, including stricter school vaccination requirements and increased accessibility to vaccines. These efforts aim to ensure that a larger portion of the population is up to date on their vaccinations. Travel-related vaccines have gained importance as international travel has become more common among Japanese citizens. People often seek vaccinations when travelling abroad to protect themselves from diseases prevalent in other regions. The economic impact of vaccine-preventable diseases, such as missed workdays and healthcare costs, has prompted some individuals and employers to prioritise vaccination. The government recommends and sometimes mandates certain vaccines, especially for schoolchildren. These recommendations and requirements play a significant role in driving vaccine demand. Routine health check-ups and screenings are common in Japan, and vaccines are often included in these preventive healthcare measures, leading to higher vaccine demand. Japan has a rapidly ageing population, and older adults are more susceptible to certain vaccine-preventable diseases. This demographic trend drives demand for vaccines targeting diseases more common among older adults, such as influenza and pneumonia. Japanese citizens travelling abroad often require vaccines to protect themselves from diseases prevalent in other regions. This has led to increased demand for travel vaccines. Japan has introduced stricter school vaccination requirements to improve vaccine coverage among school-age children, which helps protect the population from vaccine-preventable diseases. The economic impact of vaccine-preventable diseases, such as missed workdays and healthcare costs, has prompted some individuals and employers to prioritise vaccination.

What's Inside a Actual Market Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Based on the route of administration, they are segmented into intramuscular and subcutaneous administration, oral administration, and others. In Japan, intramuscular and subcutaneous vaccinations lead the vaccine market as the routes of administration. Japan has a robust routine immunisation programme that includes a schedule of vaccinations for various age groups. Many vaccines in the programme are traditionally administered via IM or SC injection. Certain vaccines, such as those for diphtheria, tetanus, pertussis, polio, and hepatitis B, are designed for IM or SC administration. These vaccines protect against diseases that are part of Japan's recommended vaccination schedule. Japan has a well-developed healthcare infrastructure with trained healthcare professionals who can administer vaccines effectively through IM and SC injections. This infrastructure supports efficient vaccine delivery. According to the report, types are segmented into multivalent vaccines and monovalent vaccines, among them. In this country, multivalent vaccines are the leading market. Multivalent vaccines combine protection against multiple diseases into a single vaccine, reducing the number of shots needed. This simplification is particularly advantageous for children and adolescents, as it minimises the discomfort and inconvenience associated with multiple injections. Japan has a relatively high population density, and healthcare resources are efficiently utilised through the use of combination vaccines, which require fewer healthcare visits and syringes. Japan's national immunisation programme includes a comprehensive schedule of vaccines for children, including multivalent vaccines. These vaccines protect against diseases like diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B (Hib), and hepatitis B. In terms of disease types, they include the rotavirus, pneumococcal diseases, cancer, influenza, diphtheria, pertussis, and tetanus, the human papilloma virus (HPV), hepatitis, shingles, meningococcal diseases, varicella, mumps, and others. In Japan, hepatitis is increasing the demand for vaccines in the country. Hepatitis B virus (HBV) infection has been a significant public health concern in Japan, with certain regions having relatively high prevalence rates. Chronic hepatitis B can lead to serious liver diseases, including cirrhosis and liver cancer, making vaccination a critical strategy for disease prevention. Japan has included hepatitis B vaccination as part of its national immunisation program. This programme targets infants and adolescents, aiming to provide immunity early in life and reduce the risk of HBV transmission. Japan's healthcare system emphasises the importance of early diagnosis and vaccination against hepatitis B, especially among high-risk populations. Healthcare providers actively screen individuals for HBV infection and offer vaccination as a preventive measure. Certain professions in Japan, such as healthcare workers, may be at higher risk of exposure to hepatitis B. Occupational vaccination programmes are in place to protect these individuals. Some hepatitis B vaccines are included in combination vaccines, such as the pentavalent vaccine, which also protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B (Hib). This simplifies the vaccination schedule and increases the coverage rate. Japan has one of the world's largest and fastest-ageing populations. This demographic trend presents an opportunity for vaccine manufacturers to develop and market vaccines targeting diseases more common among older adults, such as influenza, pneumonia, and shingles. Japan has a high healthcare expenditure per capita. As the population continues to age and healthcare needs increase, there is a growing demand for healthcare services, including vaccines. The Japanese government actively supports vaccination programmes through funding, recommendations, and mandates. Government initiatives can drive increased demand for vaccines. Japan's commitment to global health initiatives positions the country as a key player in international vaccination efforts. This involvement can lead to collaborations and opportunities in vaccine research, development, and distribution. Historically, vaccine hesitancy has been a challenge in Japan, especially following adverse events related to certain vaccines. Addressing vaccine hesitancy through public education campaigns remains a priority. Japan has a stringent vaccine approval process, which can lead to delays in introducing new vaccines to the market. This process can be challenging for vaccine manufacturers. The global vaccine market is competitive, and Japanese manufacturers may face competition from multinational pharmaceutical companies.

Make this report your own

We're excited to discuss your needs and our solutions. Let's schedule a call.

Kripa Shah

Kripa Shah

Senior Analyst

Based on the technology, it is segmented into conjugate vaccines, inactivated and subunit vaccines, live-attenuated vaccines, recombinant vaccines, and toxoid vaccines. In Japan, the toxoid vaccine market is growing with a significant market share. Japan has a very high vaccination rate for toxoid vaccines, such as the diphtheria-tetanus-pertussis (DTaP) vaccine. This is due to a number of factors, including government support for vaccination programmes, high public awareness of the importance of vaccination, and the strong trust that the Japanese people have in their healthcare system. Japanese citizens are travelling more frequently than ever before, and this is increasing the risk of exposure to diseases such as diphtheria and tetanus, which are still common in some parts of the world. This is also driving demand for toxoid vaccines in Japan. New toxoid vaccines are being developed, such as the combination DTaP-inactivated poliovirus vaccine (DTaP-IPV). These new vaccines are expected to boost demand for toxoid vaccines in Japan. The Japanese government provides financial support to manufacturers of toxoid vaccines, and this is helping to drive the growth of the market. The Japanese government and other organisations run public awareness campaigns to educate the public about the importance of toxoid vaccines. This is also helping to drive the growth of the market. According to the report, the end user is segmented into adult and paediatric. In Japan, paediatrics is the leading end user of Vaccines. Japan has well-established routine childhood vaccination programmes that recommend and often require vaccines for infants and young children. These programmes include vaccines against diseases such as measles, mumps, rubella, diphtheria, pertussis, tetanus, and more. Paediatricians are the primary healthcare providers responsible for administering these vaccines. Japanese schools, both public and private, often have vaccination requirements for students. Children must provide proof of vaccination or immunity to certain diseases before attending school. This ensures that a large portion of the paediatric population receives the recommended vaccines. There is a strong cultural emphasis on child health in Japan, with parents and the government prioritising the well-being of children. Preventive healthcare, including vaccination, is seen as a crucial aspect of child health. Japan has a well-developed healthcare infrastructure with a network of paediatric clinics and hospitals that specialise in child healthcare. Parents have easy access to healthcare services for their children, including vaccinations. Distribution channels include hospital pharmacy, retail pharmacy, institutional sales, and others. In Japan, hospital pharmacy is a growing market, and all residents have access to healthcare thanks to the country's universal healthcare system. The foundation of this system and the main source of medical treatment are hospitals. Vaccinations are frequently given to patients while they are in the hospital, guaranteeing widespread immunisation coverage. Hospitals are staffed with trained healthcare professionals, including doctors and nurses, who have the expertise to administer vaccines safely and effectively. This expertise instills confidence in patients and their families. Hospitals play a crucial role in administering vaccines as part of routine childhood vaccination programs. Children often receive their scheduled vaccinations during well-baby check-ups and other paediatric visits to hospitals. Hospitals have the necessary infrastructure and equipment to store vaccines at the recommended temperatures, ensuring the vaccines' efficacy and safety. Furthermore, the healthcare system in Japan maintains high standards of quality and safety, which extend to vaccine distribution and administration in hospitals and pharmacies.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Kripa Shah

Considered in this report: • Geography: Japan • Historic year: 2017 • Base year: 2022 • Estimated year: 2023 • Forecast year: 2028 Aspects covered in this report: • Japan Vaccines market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Technology • Conjugate vaccines • Inactivated & Subunit vaccines • Live Attenuated vaccines • Recombinant vaccines • Toxoid vaccines • Viral vector vaccines • Others By Route of Administration • Intramuscular and Subcutaneous Administration • Oral Administration • Others By Disease • Rotavirus • Pneumococcal diseases • Cancer • Influenza • Diphtheria, Pertussis, and Tetanus (DTP) • Human Papilloma Virus (HPV) • Hepatitis • Shingles • Meningococcal diseases • Varicella (Chicken Pox) • Mumps • Others By Type • Multivalent vaccines • Monovalent vaccines By End-User Type • Paediatrics • Adults By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy • Others The approach of the report: This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources. Intended audience: This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

Table of Contents

  • Table of Contents
  • 1. Executive Summary
  • 2. Market Structure
  • 2.1. Market Considerate
  • 2.2. Assumptions
  • 2.3. Limitations
  • 2.4. Abbreviations
  • 2.5. Sources
  • 2.6. Definitions
  • 2.7. Geography
  • 3. Research Methodology
  • 3.1. Secondary Research
  • 3.2. Primary Data Collection
  • 3.3. Market Formation & Validation
  • 3.4. Report Writing, Quality Check & Delivery
  • 4. Japan Macro Economic Indicators
  • 5. Market Dynamics
  • 5.1. Key Findings
  • 5.2. Key Developments - 2021
  • 5.3. Market Drivers & Opportunities
  • 5.4. Market Restraints & Challenges
  • 5.5. Market Trends
  • 5.6. Covid-19 Effect
  • 5.7. Supply chain Analysis
  • 5.8. Policy & Regulatory Framework
  • 5.9. Industry Experts Views
  • 6. Japan Vaccines Market Overview
  • 6.1. Market Size By Value
  • 6.2. Market Size and Forecast By Technology
  • 6.3. Market Size and Forecast By End-User
  • 6.4. Market Size and Forecast By Distribution Channel
  • 6.5. Market Size and Forecast By Type
  • 6.6. Market Size and Forecast By Route of Administration
  • 6.7. Market Size and Forecast By Disease
  • 7. Japan Vaccines Market Segmentations
  • 7.1. Japan Vaccines Market, By Technology
  • 7.1.1. Japan Vaccines Market Size, By Conjugate Vaccines, 2017-2028
  • 7.1.2. Japan Vaccines Market Size, By Inactivated & Subunit Vaccines, 2017-2028
  • 7.1.3. Japan Vaccines Market Size, By Live Attenuated Vaccines, 2017-2028
  • 7.1.4. Japan Vaccines Market Size, By Recombinant Vaccines, 2017-2028
  • 7.1.5. Japan Vaccines Market Size, By Toxoid Vaccines, 2017-2028
  • 7.2. Japan Vaccines Market, By End-User
  • 7.2.1. Japan Vaccines Market Size, By Pediatric Vaccines, 2017-2028
  • 7.2.2. Japan Vaccines Market Size, By Adult Vaccines, 2017-2028
  • 7.3. Japan Vaccines Market, By Distribution Channel
  • 7.3.1. Japan Vaccines Market Size, By Hospital Pharmacy, 2017-2028
  • 7.3.2. Japan Vaccines Market Size, By Retail Pharmacy, 2017-2028
  • 7.3.3. Japan Vaccines Market Size, By Institutional Sales, 2017-2028
  • 7.3.4. Japan Vaccines Market Size, By Others, 2017-2028
  • 7.4. Japan Vaccines Market, By Type
  • 7.4.1. Japan Vaccines Market Size, By Multivalent vaccines, 2017-2028
  • 7.4.2. Japan Vaccines Market Size, By Monovalent vaccines, 2017-2028
  • 7.5. Japan Vaccines Market, By Route of Administration
  • 7.5.1. Japan Vaccines Market Size, By Intramuscular and Subcutaneous Administration, 2017-2028
  • 7.5.2. Japan Vaccines Market Size, By Oral Administration, 2017-2028
  • 7.5.3. Japan Vaccines Market Size, By Others, 2017-2028
  • 7.6. Japan Vaccines Market, By Route of Disease
  • 7.6.1. Japan Vaccines Market Size, By Rotavirus, 2017-2028
  • 7.6.2. Japan Vaccines Market Size, By Pneumococcal diseases, 2017-2028
  • 7.6.3. Japan Vaccines Market Size, By Cancer, 2017-2028
  • 7.6.4. Japan Vaccines Market Size, By Influenza, 2017-2028
  • 7.6.5. Japan Vaccines Market Size, By Rotavirus, 2017-2028
  • 7.6.6. Japan Vaccines Market Size, By Diphtheria, Pertussis, and Tetanus (DTP), 2017-2028
  • 7.6.7. Japan Vaccines Market Size, By Human Papilloma Virus (HPV), 2017-2028
  • 7.6.8. Japan Vaccines Market Size, By Hepatitis, 2017-2028
  • 7.6.9. Japan Vaccines Market Size, By Shingles, 2017-2028
  • 7.6.10. Japan Vaccines Market Size, By Meningococcal diseases, 2017-2028
  • 7.6.11. Japan Vaccines Market Size, By Varicella (Chicken Pox), 2017-2028
  • 7.6.12. Japan Vaccines Market Size, By Mumps, 2017-2028
  • 7.6.13. Japan Vaccines Market Size, By Others, 2017-2028
  • 8. Japan Vaccines Market Opportunity Assessment
  • 8.1. By Technology, 2023 to 2028
  • 8.2. By End-User, 2023 to 2028
  • 8.3. By Distribution Channel, 2023 to 2028
  • 8.4. By Type, 2023 to 2028
  • 8.5. By Route of Administration, 2023 to 2028
  • 8.6. By Route of Administration, 2023 to 2028
  • 9. Competitive Landscape
  • 9.1. Porter's Five Forces
  • 9.2. Company Profile
  • 9.2.1. Company 1
  • 9.2.2. Company 2
  • 9.2.3. Company 3
  • 9.2.4. Company 4
  • 9.2.5. Company 5
  • 9.2.6. Company 6
  • 9.2.7. Company 7
  • 9.2.8. Company 8
  • 10. Strategic Recommendations
  • 11. Disclaimer

List of Table
Table 1 : Influencing Factors for Global Vaccines Market, 2022
Table 2: Japan Vaccines Market Size and Forecast By Technology (2017, 2022 & 2028F)
Table 3: Japan Vaccines Market Size and Forecast By End-User (2017, 2022 & 2028F)
Table 4: Japan Vaccines Market Size and Forecast By Distribution Channel (2017, 2022 & 2028F)
Table 5: Japan Vaccines Market Size and Forecast By Type (2017, 2022 & 2028F)
Table 6: Japan Vaccines Market Size and Forecast By Route of Administration (2017, 2022 & 2028F)
Table 7: Japan Vaccines Market Size and Forecast By Disease (2017, 2022 & 2028F)
Table 8: Japan Vaccines Market Size of Conjugate Vaccines (2017 to 2028) in USD Million
Table 9: Japan Vaccines Market Size of Inactivated & Subunit Vaccines (2017 to 2028) in USD Million
Table 10: Japan Vaccines Market Size of Live Attenuated Vaccines (2017 to 2028) in USD Million
Table 11: Japan Vaccines Market Size of Recombinant Vaccines (2017 to 2028) in USD Million
Table 12: Japan Vaccines Market Size of Toxoid Vaccines (2017 to 2028) in USD Million
Table 13: Japan Vaccines Market Size of Pediatric Vaccines (2017 to 2028) in USD Million
Table 14: Japan Vaccines Market Size of Adult Vaccines (2017 to 2028) in USD Million
Table 15: Japan Vaccines Market Size of Hospital Pharmacy (2017 to 2028) in USD Million
Table 16: Japan Vaccines Market Size of Retail Pharmacy (2017 to 2028) in USD Million
Table 17: Japan Vaccines Market Size of Institutional Sales (2017 to 2028) in USD Million
Table 18: Japan Vaccines Market Size of Others (2017 to 2028) in USD Million
Table 19: Japan Vaccines Market Size of Multivalent vaccines (2017 to 2028) in USD Million
Table 20: Japan Vaccines Market Size of Monovalent vaccines (2017 to 2028) in USD Million
Table 21: Japan Vaccines Market Size of Intramuscular and Subcutaneous Administration (2017 to 2028) in USD Million
Table 22: Japan Vaccines Market Size of Oral Administration (2017 to 2028) in USD Million
Table 23: Japan Vaccines Market Size of Others (2017 to 2028) in USD Million
Table 24: Japan Vaccines Market Size of Rotavirus (2017 to 2028) in USD Million
Table 25: Japan Vaccines Market Size of Pneumococcal diseases (2017 to 2028) in USD Million
Table 26: Japan Vaccines Market Size of Cancer (2017 to 2028) in USD Million
Table 27: Japan Vaccines Market Size of Influenza (2017 to 2028) in USD Million
Table 28: Japan Vaccines Market Size of Rotavirus (2017 to 2028) in USD Million
Table 29: Japan Vaccines Market Size of Diphtheria, Pertussis, and Tetanus (DTP) (2017 to 2028) in USD Million
Table 30: Japan Vaccines Market Size of Human Papilloma Virus (HPV) (2017 to 2028) in USD Million
Table 31: Japan Vaccines Market Size of Hepatitis (2017 to 2028) in USD Million
Table 32: Japan Vaccines Market Size of Shingles (2017 to 2028) in USD Million
Table 33: Japan Vaccines Market Size of Meningococcal diseases (2017 to 2028) in USD Million
Table 34: Japan Vaccines Market Size of Varicella (Chicken Pox) (2017 to 2028) in USD Million
Table 35: Japan Vaccines Market Size of Mumps (2017 to 2028) in USD Million
Table 36: Japan Vaccines Market Size of Others (2017 to 2028) in USD Million

List of Figures
Figure 1: Japan Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Million)
Figure 2: Market Attractiveness Index, By Technology
Figure 3: Market Attractiveness Index, By End-User
Figure 4: Market Attractiveness Index, By Distribution Channel
Figure 5: Market Attractiveness Index, By Type
Figure 6: Market Attractiveness Index, By Route of Administration
Figure 7: Market Attractiveness Index, By Route of Administration
Figure 8: Porter's Five Forces of Japan Vaccines Market
Logo

Japan Vaccines Market Research Report, 2028

Contact usWe are friendly and approachable, give us a call.